-
公开(公告)号:DE10344848A1
公开(公告)日:2005-04-14
申请号:DE10344848
申请日:2003-09-26
Applicant: SOLVAY PHARM GMBH
Inventor: HOELTHE DAGMAR , FISCHER YVAN , ZIEGLER DIETER , WESKE MICHAEL , MICHAELIS KATRIN , KARIMI-NEJAD YASMIN , MESSINGER JOSEF , PAHL AXEL , HOEFER CONSTANZE
Abstract: Amidomethyl substituted 1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-n-acetic acid derivatives (I) and their salts are new. Amidomethyl substituted 1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-n-acetic acid derivatives of formula (I) and their salts are new. [Image] R 1>, R 4>H or a group forming a biolabile ester; and either R 2>H, 1-4C alkyl or 1-4C hydroxyalkyl (where the OH is optionally esterified with 2-4C alkanoyl or an amino acid residue); and R 3>1-4C alkyl, 1-4C alkoxy-1-4C alkyl; 1-4C hydroxyalkyl (optionally substituted by a second hydroxyl group and the hydroxyl groups of which are each optionally esterified with 2-4C alkanoyl or an amino acid residue); (0-4C alkyl) 2amino-1-6C alkyl, 3-7C cycloalkyl(1-4C alkyl), phenyl-1-4C alkyl or phenylcarbonylmethyl (where the phenyl group is optionally substituted 1-2 times by 1-4C alkyl, 1-4C alkoxy and/or halo), naphthyl-1-4C alkyl, 3-6C oxoalkyl or 2-oxoazepanyl; or R 2> + R 3>4-7C alkylene (where the methylene groups are optionally replaced 1-2 times by carbonyl, nitrogen, oxygen and/or sulfur and/or which are optionally substituted once by OH, which is optionally esterified with 2-4C alkanoyl or an amino acid residue), 1-4C alkyl; 1-4C hydroxyalkyl (where the OH group is optionally esterified with 2-4C alkanoyl or an amino acid residue); phenyl or benzyl. Independent claims are also included for: (1) preparation of (I); and (2) a carboxyalkyl-cyclopentylcarbonylamino-benzazepine-n-acetic acid derivatives of formula (II). [Image] R 1> 0> 1>, R 4> 0> 1>an acid-protecting group. ACTIVITY : Cardiovascular-Gen.; Hypotensive; Nephrotropic; Respiratory-Gen.; Endocrine-Gen.; Vasotropic; Neuroprotective; Cerebroprotective; Antiinflammatory; Nootropic; Antiarteriosclerotic; Anti-HIV; Muscular-Gen.; Anticonvulsant; Vulnerary; Antiparkinsonian; Antiinflammatory; Hepatotropic; Antibacterial; Virucide; CNS-Gen.; Dermatological; Antiemetic; Cytostatic; Gastrointestinal-Gen.; Antiulcer; Antimicrobial; Immunosuppressive; Antialcoholic; Antiarthritic; Osteopathic; Immunostimulant; Hemostatic; Antirheumatic; Cardiant; Antithyroid; Anabolic; Hypertensive; Antidiabetic; Antipsoriatic; Gynecological; Antiallergic; Auditory; Antianemic; Antiseborrheic; Keratolytic; Vasotropic; Anticoagulant; Vulnerary; Ophthalmological; Metabolic; Protozoacide; Fungicide; Antidote; Antirheumatic. MECHANISM OF ACTION : Neutral endopeptidase (NEP) inhibitor; Human soluble endopeptidase (hSEP) inhibitor. The ability of (I) to inhibit (NEP) was assessed in vitro. The results showed that median inhibitory concentration (IC 5 0) value of (I) was less than 1 nM.
-
公开(公告)号:AR045798A1
公开(公告)日:2005-11-16
申请号:ARP040103409
申请日:2004-09-22
Applicant: SOLVAY PHARM GMBH
Inventor: HOLTJE DAGMAR , FISCHER IVAN , ZIEGLER DIETER , WESKE MICHAEL , MICHAELIS KATRIN , MESSINGER JOSEF , PAHL AXEL , KARIMI-NEJAD YASMIN
IPC: A61K38/00 , A61P9/12 , C07K5/02 , C07K5/078 , C07K5/06 , C07K1/06 , A61K38/05 , A61K31/55 , A61P9/00 , A61P15/00 , A61P25/28
Abstract: Se describen compuestos con actividad inhibidora de la endopeptidasa neutra (NEP) y/o la endopeptidasa humana soluble (hSEP), así como medicamentos que contienen estos compuestos, en particular medicamentos adecuados para tratamiento o prevención de enfermedades cardiovasculares, disfunción sexual y/o condiciones adversas asociadas con apoptosis. Reivindicación 1: Compuestos de la fórmula general (1), en donde: R1 es hidrógeno o un grupo formador de un éster biolábil; R2 es hidrógeno, alquilo C1-4 o hidroxialquilo C1-4, cuyo grupo hidroxilo está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; y R3 es alquilo C1-4; alcoxi(C1-4)-alquilo(C1-4); hidroxialquilo C1-4, que está sustituido opcionalmente con un segundo grupo hidroxilo y cuyos grupos hidroxilo están esterificados cada uno opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; (alquil C0-4)2amino-alquilo(C1-4); cicloalquilo C3-7; cicloalquil(C3-7)-alquilo(C1-4); fenil-alquilo(C1-4), cuyo grupo fenilo está sustituido opcionalmente 1-2 veces con alquilo C1-4, alcoxi C1-4 y/o halógeno; naftil-alquilo(C1-4); oxoalquilo C3-6; fenilcarbonilmetilo, cuyo grupo fenilo está sustituido opcionalmente 1-2 veces con alquilo C1-4, alcoxi C1-4 y/o halógeno, o 2-oxoazepanilo; o R2 y R3 juntos son alquileno C4-7, cuyos grupos metileno están reemplazados opcionalmente 1-2 veces por carbonilo, nitrógeno, oxígeno y/o azufre, y/o que están sustituidos opcionalmente una sola vez con hidroxi, que está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; alquilo C1-4; hidroxialquilo C1-4, cuyo grupo hidroxilo está esterificado opcionalmente con alcanoilo C2-4 o un residuo de aminoácido; fenilo o bencilo; y R4 es hidrógeno o un grupo formador de un éster biolábil, y sales fisiológicamente compatibles de los ácidos de fórmula (1) y/o sales de adición de ácido fisiológicamente compatibles de los compuestos de fórmula (1).
-
公开(公告)号:AU2004276002A1
公开(公告)日:2005-04-07
申请号:AU2004276002
申请日:2004-09-23
Applicant: SOLVAY PHARM GMBH
Inventor: HOELTJE DAGMAR , ZIEGLER DIETER , MICHAELIS KATHRIN , PAHL AXEL , MESSINGER JOSEF , WESKE MICHAEL , TURSKI LECHOSLAW , HOEFER CONSTANZE , FISCHER YVAN , KARIMI-NEJAD YASMIN , IKONOMIDOU HRISSANTHI
Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
公开(公告)号:NO20061821L
公开(公告)日:2006-06-22
申请号:NO20061821
申请日:2006-04-25
Applicant: SOLVAY PHARM GMBH
Inventor: TURSKI LECHOSLAW , ZIEGLER DIETER , MESSINGER JOSEF , WESKE MICHAEL , PAHL AXEL , HOELTJE DAGMAR , FISCHER YVAN , MICHAELIS KATHRIN , KARIMI-NEJAD YASMIN , HOEFER CONSTANZE , IKONOMIDOU HRISSANTHI
Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
公开(公告)号:HK1096105A1
公开(公告)日:2007-05-25
申请号:HK07103455
申请日:2007-03-30
Applicant: SOLVAY PHARM GMBH
Inventor: HOELTJE DAGMAR , FISCHER YVAN , ZIEGLER DIETER , WESKE MICHAEL , MICHAELIS KATHRIN , KARIMI-NEJAD YASMIN , MESSINGER JOSEF , PAHL AXEL , HOEFER CONSTANZE , IKONOMIDOU HRISSANTHI , TURSKI LECHOSLAW
IPC: A61K20090101 , A61K38/00 , A61P20090101 , A61P9/12 , C07K20090101 , C07K5/02 , C07K5/078
Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
公开(公告)号:NO20061821A
公开(公告)日:2006-06-22
申请号:NO20061821
申请日:2006-04-25
Applicant: SOLVAY PHARM GMBH
Inventor: TURSKI LECHOSLAW , ZIEGLER DIETER , MESSINGER JOSEF , WESKE MICHAEL , PAHL AXEL , HOELTJE DAGMAR , FISCHER YVAN , MICHAELIS KATHRIN , KARIMI-NEJAD YASMIN , HOEFER CONSTANZE , IKONOMIDOU HRISSANTHI
CPC classification number: C07K5/06139 , A61K38/00 , C07K5/0222 , Y02A50/409
Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
公开(公告)号:CA2539895A1
公开(公告)日:2005-04-07
申请号:CA2539895
申请日:2004-09-23
Applicant: SOLVAY PHARM GMBH
Inventor: FISCHER YVAN , MICHAELIS KATHRIN , TURSKI LECHOSLAW , IKONOMIDOU HRISSANTHI , HOELTJE DAGMAR , PAHL AXEL , MESSINGER JOSEF , KARIMI-NEJAD YASMIN , HOEFER CONSTANZE , WESKE MICHAEL , ZIEGLER DIETER
Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
公开(公告)号:AU2004276002B2
公开(公告)日:2010-07-22
申请号:AU2004276002
申请日:2004-09-23
Applicant: SOLVAY PHARM GMBH
Inventor: HOELTJE DAGMAR , ZIEGLER DIETER , MICHAELIS KATHRIN , PAHL AXEL , MESSINGER JOSEF , WESKE MICHAEL , TURSKI LECHOSLAW , HOEFER CONSTANZE , FISCHER YVAN , KARIMI-NEJAD YASMIN , IKONOMIDOU HRISSANTHI
Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
公开(公告)号:UA85195C2
公开(公告)日:2009-01-12
申请号:UAA200604364
申请日:2004-09-23
Applicant: SOLVAY PHARM GMBH
Inventor: HOELTJE DAGMAR , FISCHER YVAN , CYGLER DITER , WESKE MICHAEL , MICHAELIS KATHRIN , KARIMI-NEJAD YASMIN , MESSINGER JOSEF , PAHL AXEL , HOEFER CONSTANZE , IKONOMIDOU HRISSANTHI , TURSKI LECHOSLAW
Abstract: Взаявкеописаныновыесоединения, которыепроявляютингибирующеевлияниенанейтральнуюэндопептидазу (НЭП) и/илирастворимуюэндопептидазучеловека (лРЭП), общейформулыІ EMBED ISISServer , Ів которойзаместители R1, R2, R3 и R4 имеютзначения, указанныев описании, атакжелекарственныесредства, которыесодержатэтисоединения, вчастностилекарственныесредства, пригодныедлялеченияилипредупреждениясердечно-сосудистыхзаболеваний, половойдисфункциии/илипатологическихсостояний, связанныхс апоптозом.
-
公开(公告)号:BRPI0414744A
公开(公告)日:2006-11-21
申请号:BRPI0414744
申请日:2004-09-23
Applicant: SOLVAY PHARM GMBH
Inventor: HOELTJE DAGMAR , FISCHER YVAN , ZIEGLER DIETER , WESKE MICHAEL , MICHAELIS KATHRIN , KARIMI-NEJAD YASMIN , MESSINGER JOSEF , PAHL AXEL , HOEFER CONSTANZE , IKONOMIDOU HRISSANTHI , TURSKI LECHOSLAW
Abstract: Described are novel compounds with neutral endopeptidase (NEP) and/or human soluble endopeptidase (hSEP) inhibitory activity of the general formula (I), wherein the substituents R , R , R and R have the meanings given in the description and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardiovascular diseases, sexual dysfunction and/or adverse conditions associated with apoptosis.
-
-
-
-
-
-
-
-
-